Jiuzhou Pharmaceutical (603456.SH) subsidiary plans to invest in Jiaxing Longfeng Venture Capital Partnership (limited partnership)

Zhitong Finance App News, Jiuzhou Pharmaceutical (603456.SH) announced that Hongzhou Investment, a wholly-owned subsidiary of the company, plans to participate in the Jiaxing Longfeng Venture Capital Partnership (Limited Partnership). The total amount of capital pledged by the partnership is 77 million yuan (including this investment). As a limited partner, Hongzhou Investment will pledge 10 million yuan with its own capital, accounting for 12.987% of the total investment pledged by the partnership.

Partnership investment direction: It mainly invests in pharmaceutical-related fields such as new drug research and development and medical device research and development projects, mainly including but not limited to high-quality emerging medical enterprises, including but not limited to new drugs, innovative drugs, medical devices, medical services, diagnosis, biotechnology, and pharmaceutical outsourcing R&D enterprises.